ABSTRACT
BACKGROUND: ⢠The ERCP even when done by experienced professionals, fails in 10% of cases. BACKGROUND: ⢠Until the development of the EUS-BD, PTBD had a role as a rescue therapy, despite a high rate of adverse events. BACKGROUND: ⢠The EUS-BD is safe and has similar efficacy, when compared to PTBD and should be performed immediately after ERCP failure. BACKGROUND: ⢠A doctor with skills in both methods (ERCP/EUS) is needed to determine the best EUS-guided therapeutic option.
Subject(s)
Adenocarcinoma , Pancreatic Neoplasms , Physicians , Humans , Cholangiopancreatography, Endoscopic Retrograde , Endosonography , Pancreatic Neoplasms/diagnostic imaging , Pancreatic Neoplasms/surgery , Adenocarcinoma/diagnostic imaging , Adenocarcinoma/surgeryABSTRACT
Primary pancreatic lymphoma is a rare type of cancer, that accounts for 0.1-0.5% of lymphomas and about 0.2% of all primary pancreatic tumors. Diffuse Large B-cell Lymphoma is the most common subtype. The diagnosis is possible if the lymphoma is located in the pancreas, but the differential diagnosis with pancreatic ductal adenocarcinoma is difficult. The diagnostic accuracy of endosonography-guided fine needle aspiration is inadequate, and thus it is common to diagnose these masses only after surgical resection. The endosonography-guided tissue acquisition allows greater accuracy in the pancreatic masses, as it determines optimal access to histological analysis using tissue in paraffin blocks for complementary immunohistochemical, and molecular tests. Thus, this elaborate diagnostic environment allows the adoption of appropriate treatment strategies for patients with this condition. The authors describe four cases of primary pancreatic lymphoma indicated for surgical resection due to suspected pancreatic cancer, with the diagnosis of Diffuse Large B-cell Lymphoma obtained by endosonography-guided tissue acquisition, changing the therapeutic strategy through the adoption of adequate chemotherapy treatment with good progress.